SUNFISH: Risdiplam Meets Primary Endpoint in SMA SUNFISH: Risdiplam Meets Primary Endpoint in SMA

Risdiplam, an oral investigational agent designed to increase and sustain SMN protein levels of patients with spinal muscular atrophy (SMA), met the primary endpoint in the pivotal part 2 of the SUNFISH trial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news